Back to top
more

Horizon Pharma Public Limited Company (HZNP)

(Delayed Data from NSDQ)

$26.54 USD

26.54
1,058,972

+0.55 (2.12%)

Updated May 3, 2019 04:00 PM ET

After-Market: $26.52 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

M&A, Innovation & New Drugs to Drive Pharma Stocks

The new tax law, which cuts the corporate tax rate from 35% to 21% and encourages companies to bring back cash held overseas at a one-time tax rate of 10%, is expected to spur merger activity.

    5 Low Price-to-Book Stocks With Great Growth Prospects

    P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.

      Horizon Pharma (HZNP) Tops Q4 Earnings, Provides 2018 View

      Horizon Pharma (HZNP) Q4 results are driven by growth from the orphan unit and the rheumatology business.

        Horizon Pharma (HZNP) Tops Q4 Earnings, Revenues Beat

        Horizon Pharma (HZNP) topped earnings and sales in the fourth quarter.

          Is a Beat in Store for Horizon Pharma (HZNP) in Q4 Earnings?

          On Horizon Pharma's (HZNP) fourth-quarter 2017 earnings call, investors focus will be on the performance of its business units and key products.

            Horizon Pharma Gets FDA Nod for Procysbi Label Expansion

            The FDA approves label expansion for Horizon Pharma's (HZNP) Procysbi (cysteamine bitartrate) delayed-release capsules for children aged a year and older with nephropathic cystinosis.

              Horizon Pharma (HZNP) Tops Q3 Earnings & Sales, Ups View

              Horizon Pharma (HZNP) Q3 results were driven by growth from the orphan and rheumatology business.

                Ekta Bagri headshot

                Horizon (HZNP) Tops Q3 Earnings, Shares Up

                Horizon Pharma (HZNP) topped earnings and sales in the third quarter. Consequently, share are trading up in pre-market trading.

                  Key Predictions for Q3 Earnings Reports of MYL, HZNP & KERX

                  The pharma/biotech industry has witnessed strong Q3 results with many companies beating estimates for earnings and sales. Let's see if generic maker Mylan and other small companies follow suit.

                    Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store? (revised)

                    Horizon Pharma???s shares have declined 12% in the year so far, underperforming the industry???s gain of 0.9%.

                      Horizon Pharma (HZNP) Q3 Earnings: A Disappointment in Store?

                      Horzion Pharma's (HZNP) primary care business is under pressure and we expect earnings to disappoint in the third quarter.

                        Is Horizon Pharma (HZNP) A Suitable Pick for Value Investors?

                        Let's find out if Horizon Pharma Public Limited Company (HZNP) stock is a good choice for value-oriented investors right now

                          Horizon Pharma (HZNP) Soars: Stock Adds 10.5% in Session

                          Horizon Pharma Public Limited Company (HZNP) was a big mover last session, as the company saw its shares rise nearly 11% on the day amid huge volumes.

                            Horizon Pharma (HZNP) Q2 Earnings & Sales Top, Raises View

                            Horizon Pharma plc (HZNP) topped both earnings and sales estimate in second-quarter 2017 and raised its sales guidance for 2017.

                              Ekta Bagri headshot

                              Horizon Pharma (HZNP) Tops Earnings in Q2, Shares Up

                              Horizon Pharma (HZNP) topped earnings and sales estimates in the second quarter of 2017 and upped its annual sales guidance.

                                Can Horizon Pharma (HZNP) Spring a Surprise in Q2 Earnings?

                                Horizon Pharma (HZNP) is set to report second-quarter results next week and we expect investor focus on sales of key drugs.

                                  Horizon Pharma Gets Health Canada Approval for Procysbi

                                  Horizon Pharma plc (HZNP), announced that it has received approval in Canada for Procysbi (cysteamine delayed-release capsules) for the treatment of nephropathic cystinosis in adults and children of 2 years old and more.

                                    Horizon Pharma (HZNP) Up 11.3% Since Earnings Report: Can It Continue?

                                    Horizon Pharma (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                                      Falling Earnings Estimates Signal Weakness Ahead for Horizon Pharma (HZNP)

                                      One stock that you may want to consider dropping is Horizon Pharma Public Limited Company (HZNP), which has witnessed a significant price decline in the past four weeks

                                        Horizon (HZNP) Sells European Rights for Procysbi & Quinsair

                                        Horizon Pharma plc (HZNP) signed an agreement with Chiesi Farmaceutici S.p.A. to sell European rights for Procysbi and Quinsair.

                                          Horizon (HZNP) Falls on Q1 Earnings Miss, Guidance Trimmed

                                          Horizon Pharma plc (HZNP) reported first-quarter 2017 earnings of 21 cents per share, down from 25 cents in the year-ago quarter. Reported earnings also missed the Zacks Consensus Estimate of 25 cents.

                                            Madeleine Johnson headshot

                                            Here's Why Shares of Horizon Pharma (HZNP) are Cratering Today

                                            On Monday, shares of biopharmaceutical company Horizon Pharma (HZNP) are cratering, down over 34% to $10.09 per share in afternoon trading after they reported first-quarter financial results that missed expectations.

                                              Madhu Goel headshot

                                              Horizon Pharma (HZNP) Misses Q1 Earnings, Shares Crash

                                              Horizon Pharma???s first-quarter 2017 earnings missed expectations.

                                                Mylan (MYL) Q1 Earnings: Will the Stock Pull a Surprise?

                                                Mylan N.V. (MYL) is scheduled to report first-quarter 2017 results on May 10, before the market opens.

                                                  Should You Buy Horizon Pharma PLC (HZNP) Ahead of Earnings?

                                                  Horizon Pharma PLC (HZNP) seems to be a great stock Ahead of Earnings on the back of its solid zacks rank and positive earnings ESP.